



**Citation:** Chen P-C, Li P-C, Ding D-C (2021) Pelvic inflammatory disease and causative pathogens in older women in a medical center in eastern Taiwan: A retrospective cross-sectional study. PLoS ONE 16(9): e0257627. https://doi.org/10.1371/journal.pone.0257627

**Editor:** Peter F.W.M. Rosier, University Medical Center Utrecht, NETHERLANDS

Received: April 21, 2021

Accepted: September 6, 2021

Published: September 20, 2021

Copyright: © 2021 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper.

**Funding:** DC: TCMF-EP-108-02, The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

RESEARCH ARTICLE

# Pelvic inflammatory disease and causative pathogens in older women in a medical center in eastern Taiwan: A retrospective cross-sectional study

Pei-Chen Chen<sup>1</sup>, Pei-Chen Li<sup>1</sup>, Dah-Ching Ding<sub>0</sub><sup>1,2</sup>\*

- 1 Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan, 2 Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan
- \* dah1003@yahoo.com.tw

# **Abstract**

# **Objectives**

Most research into the management of pelvic inflammatory disease (PID) is in younger women and focuses on sexually transmitted pathogens such as *N. gonorrhoeae* or *C. trachomatis*. Non-sexually transmitted bacterial pathogens and PID in older women are rarely examined. The objective of this study is to explore cervical culture pathogens in women of different age groups in a medical center in eastern Taiwan.

# **Methods**

We enrolled patients whose medical records were diagnosed with PID (ICD-9-CM 614.0 [N70.01–03], 614.1[N70.11–13], 614.9 [N73.5, N73.9]) at our hospital from October 2014 to March 2020. Patients were divided into three groups according to age: the age <25 years, age 25–44 years, and the  $\geq$  45 years group. Chi-square test, ANOVA and logistic regression were used for statistical analysis. In subgroup analysis, endocervical pathogens were further stratified into vaginal, respiratory, enteric, skin, oral, and other.

# Results

A total of 96 patients were included in the study. There were 31 patients in the age  $\geq$  45 years group, 52 patients in the age 25–44 years group, and 13 patients in the age <25 years group. Vagina and enteric pathogens were the most common pathogens among all groups. The isolated respiratory and other pathogens were more in the age  $\geq$  45 years group than in the other two groups. *Prevotella bivia* was more common in the age <25 years and 25–44 years groups.

# **Conclusions**

This may be due to different pathogeneses of PID in the age  $\geq$  45 years patients. Our study can be used as a reference for antibiotic choice of non-sexually transmitted PID and to prevent long-term sequelae of PID.

## Introduction

Pelvic inflammatory disease (PID) is an infectious disease of the pelvic cavity, including the upper genital tract. Patients typically present with pain, abnormal discharge, lower abdominal pain, and fever [1]. Women with PID are at higher risk of chronic pelvic pain, ectopic pregnancy, infertility, and internal pelvic scarring [2, 3]. PID is associated with sexual activity, multiple sexual partners, young age, and previous PID [4]. Much of the research in PID has focused primarily on young, sexually active women. Among women aged 15–29 years, there are approximately 750,000 cases of PID each year in the US [5].

The most common pathogenesis of PID is the ascending infection of *N. gonorrhoeae* or *C. trachomatis* through sexual activity. The prevalence of PID associated with the above two pathogens is less than 50% [6, 7]. Other species of pathogens may play roles in causing PID. Additionally, vaginal microbiota and pathogens play a large role in PID and other infertility-associated problems [8]. In clinical situations, direct culture bacteria from the pelvic cavity is not available. Vaginal culture is an alternative way to obtain the information of PID causing pathogens. However, the relationship between bacterial vaginosis and PID remains controversial. A previous review summarized there were four categories of PID infectious agents, including cervical, bacterial vaginosis, respiratory, and enteric pathogens [9]. These pathogens may cause PID other than *N. gonorrhoeae* and *C. trachomatis* and show equal importance in PID treatment [10]. One study also showed a 5-fold decrease of PID caused by *C. Trachomatis* with age, so it is important to evaluate the other causes of PID in older women [11].

The management for PID follows the 2021 CDC (center for disease control and prevention) sexually transmitted disease (STD) guidelines [12]. Intravenous, intramuscular or oral antibiotics are the primary treatment. However, the guidelines focus on STD-related PID in young women. Study of pathogens of PID in older women is rare. Moreover, very few studies have been done in Taiwan or other countries examining the prevalence of non-sexually transmitted pathogens in PID, particularly among older women.

Therefore, in this study, we explore the cervical culture pathogens (except N. gonorrhoeae and C. trachomatis) in different age groups (<25, 25–44, and  $\ge 45$  years) of women in our institution in eastern Taiwan and identify other bacterial pathogen in PID for accurate antibiotic treatment in different ages of women.

## Materials and methods

#### **Data sources**

We used an electronic medical history database in our hospital to retrieve the records of patients with PID over a 6-year period (2014–2020). The diagnostic codes were based on the International Classification of Diseases, Ninth and Tenth Revision, and Clinical Modification (ICD-9-CM and ICD-10-CM) during the study period. This study was approved by the Research Ethics Committee of Hualien Tzu Chi Hospital (IRB 108-201-B). The requirement for informed consent was waived due to minimal risk and approved by the Research Ethics

Committee of Hualien Tzu Chi Hospital. We confirm that all methods were performed in accordance with the relevant guidelines and regulations.

# Study design and participants

This was a retrospective cross-sectional study with chart review. The inclusion criteria were patients' medical records with the diagnosis of PID in our hospital. The exclusion criteria were patients' medical records without cervical culture data or culture revealed *N. gonorrhoeae* and *C. trachomatis*. We used the ICD-9-CM [ICD-10-CM] codes for PID (614.0 [N70.01, N70.02, N70.03], 614.1 [N70,11, N70.12, N70.13], 614.9 [N73.5, N73.9]) to recruit patients from outpatient clinics and patients admitted to our hospital from October 2014 to March 2020.

Clinical diagnostic criteria for PID included lower abdominal pain, uterine or adnexal tenderness, cervical motion tenderness, and abnormal vaginal discharge [13].

Records for microbial culture for cases of PID were retrieved and analyzed.

## **Outcome measures**

Patients were divided into three groups according to age: <25 years, 25–44 years, and  $\ge$ 45 years. The following data were collected: age, body mass index (BMI), education level, previous surgical history (gynecological or abdominal), birth history (normal spontaneous delivery [NSD] or cesarean delivery [C/S]), sexual history, number of sexual partner, smoking history, menopause, previous PID history, associated urinary tract infection (UTI), intrauterine device (IUD) placement, medical history (hypertension (HTN), diabetes mellitus (DM), or gastrointestinal problems), gynecologic structure problems (polyps or myoma), and pelvic organ prolapse.

In subgroup analysis, the endocervical pathogens were further stratified into vaginal (Peptostreptococcus species, Bacteroides species, Atopobium species, Leptotrichia species, M. hominis, Ureaplasma urealyticum, and Clostridia species), respiratory (Haemophilus influenzae, Streptococcus pneumoniae, group A Streptococci, and Staphylococcus aureus), enteric (Escherichia coli, Bacteroides fragilis, group B streptococci, and Campylobacter species), skin (Coagulase-negative staphylococci), oral (Fusobacterium species, Streptococcus staphylococci), oral Staphylococcis, Streptococcus Streptococcus Streptococcis, Streptococcis

# Statistical analyses

Statistical analysis was conducted with SPSS 25.0 (IBM, Armonk, NY, USA). The Chi-square test was used to compare categorical variables and ANOVA with the post-hoc Bonferroni test was used to compare continuous variables. Logistic regression was used to find the association between pathogens and demographics. A P-value < 0.05 was considered significant.

#### Results

Ninety-six patients were included in the study: 31 patients in the age  $\geq$ 45y group, 52 patients in the 25-44y group, and 13 patients in the <25 y group. Table 1 shows the characteristics of the patients. The number of vaginal deliveries, menopause, hypertension, and DM were significantly more common in the age  $\geq$ 45 years group than in the other two groups. UTI was common in the age <25 years group. IUD use was common in the age 25–44 years group. There were no differences in BMI, education, previous PID, number of sexual partners, history of abdominal surgery, pelvic organ prolapse, or gynecological structure problems (myoma and polyps) among the three groups.

Table 1. Demographics (n = 96).

	<25 y/o (A)	25-44 y/o (B)	≧45 y/o (C)	Total	P-value	Post-hoc
N	13	52	31	96		
Age	20.54±2.15	35.17±6.04	55.29±10.94	39.69±14.10	<0.001*	A <b<c< td=""></b<c<>
ВМІ	21.97±5.11	25.86±6.72	26.83±5.64	25.65±6.32	0.075	
BMI group	-	-	-	-	0.368	
Normal	10(83.3%)	23(46.9%)	15(51.7%)	48(53.3%)		
Underweight	0(0.0%)	3(6.1%)	0(0.0%)	3(3.3%)		
Overweight	1(8.3%)	12(24.5%)	9(31.0%)	22(24.4%)		
Obese	1(8.3%)	11(22.4%)	5(17.2%)	17(18.9%)		
Education	-	-	-	-	0.305	
Junior high school or under	2(15.4%)	8(15.4%)	11(35.5%)	21(20.8%)		
Senior high school	8(61.5%)	23(44.2%)	9(29.0%)	43(42.6%)		
College or above	2(15.4%)	12(23.1%)	5(16.1%)	20(19.8%)		
Not mentioned	1(7.7%)	9(17.3%)	6(19.4%)	17(16.8%)		
No. of NSD	0.42±1.44	1.02±1.36	1.86±1.94	1.21±1.64	0.016*	A <c< td=""></c<>
No. of C/S	0.00±0.00	0.58±0.84	0.76±1.19	0.56±0.93	0.058	
Delivery mode	-	-	-	-	0.001*	
None	11(91.7%)	13(26.0%)	4(13.8%)	28(30.8%)		
NSD	1(8.3%)	18(36.0%)	15(51.7%)	34(37.4%)		
C/S	0(0.0%)	13(26.0%)	7(24.1%)	20(22.0%)		
Both	0(0.0%)	6(12.0%)	3(10.3%)	9(9.9%)		
Menopause	-	-	-	-	<0.001*	
No	13(100.0%)	49(94.2%)	12(38.7%)	74(77.1%)		
Yes	0(0.0%)	2(3.8%)	18(58.1%)	20(20.8%)		
Not mentioned	0(0.0%)	1(1.9%)	1(3.2%)	2(2.1%)		
Previous PID	-	-	-	-	0.812	
No	3(23.1%)	20(38.5%)	12(38.7%)	35(36.5%)		
Yes	4(30.8%)	16(30.8%)	8(25.8%)	28(29.2%)		
Not mentioned	6(46.2%)	16(30.8%)	11(35.5%)	33(34.4%)		
Associated UTI	-	-	-	-	0.039*	
No	7(53.8%)	36(69.2%)	18(58.1%)	61(63.5%)		
Yes	4(30.8%)	13(25.0%)	4(12.9%)	21(21.9%)		
Not mentioned	2(15.4%)	3(5.8%)	9(29.0%)	14(14.6%)		
IUD use	-	-	-	-	0.014*	
No	13(100.0%)	44(84.6%)	23(74.2%)	80(83.3%)		
Yes	0(0.0%)	5(9.6%)	0(0.0%)	5(5.2%)		
Not mentioned	0(0.0%)	3(5.8%)	8(25.8%)	11(11.5%)		
Multisexual partner	-	-	-	-	0.059	
No	0(0.0%)	4(7.7%)	3(9.7%)	7(7.3%)		
Yes	2(15.4%)	0(0.0%)	0(0.0%)	2(2.1%)		
Not mentioned	11(84.6%)	48(92.3%)	28(90.3%)	87(90.6%)		
HTN (%)	0(0.0%)	5(9.6%)	10(32.3%)	15(15.6%)	0.004*	
DM (%)	0(0.0%)	6(11.5%)	8(25.8%)	14(14.6%)	0.039*	
Smoking	-	-	-	-	0.142	
No	9(69.2%)	32(61.5%)	25(80.6%)	66(68.8%)		
Yes	3(23.1%)	15(28.8%)	2(6.5%)	20(20.8%)		
Not mentioned	1(7.7%)	5(9.6%)	4(12.9%)	10(10.4%)		
History of GYN surgery (%)	3(23.1%)	21(40.4%)	18(58.1%)	42(43.8%)	0.060	

(Continued)

Table 1. (Continued)

	<25 y/o (A)	25-44 y/o (B)	≥45 y/o (C)	Total	P-value	Post-hoc
History of abdominal surgery (%)	2(15.4%)	4(7.7%)	2(6.5%)	8(8.3%)	0.479	
Pelvic organ prolapse (%)	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458	
GYN structure problem (%)	0(0.0%)	10(19.2%)	7(22.6%)	17(17.7%)	0.200	
GI problem (%)	0(0.0%)	1(1.9%)	0(0.0%)	1(1.0%)	1.000	
Source	-	-	-	-	0.178	
OPD	7(53.8%)	35(67.3%)	25(80.6%)	67(69.8%)		
Ward	6(46.2%)	17(32.7%)	6(19.4%)	29(30.2%)		
Operation (%)	0(0.0%)	5(9.6%)	1(3.2%)	6(6.3%)	0.495	

Data are presented as n (%) or mean ± standard deviation.

BMI: body mass index, PID: pelvic inflammatory disease, UTI: urinary tract infection, IUD, intrauterine device, HTN: hypertension, DM: diabetes mellitus, GI: gastrointestinal, GYN: gynecologic, NA: not available, NSD: normal spontaneous delivery, C/S: cesarean section.

https://doi.org/10.1371/journal.pone.0257627.t001

Table 2 shows the numbers and percentages of different categorical pathogens in PID patients among the three groups. There were 318 isolated microorganisms. There were six subgroups of pathogens, including vaginal, respiratory, enteric, skin, oral, and opportunistic human infections. The most common pathogens in PID patients in the age  $\geq$ 45y group than in the other two groups were respiratory and other pathogens (p = 0.046 and p = 0.039, respectively). The vagina, enteric, skin, and oral pathogens were no significant differences among the three groups.

<u>Table 3</u> shows the number and percentage of different categorial pathogens in the PID patients. The *Prevotella bivia* (vaginal pathogens) was more common in age <25 and 25–44

Table 2. Bacterial isolates in patients with pelvic inflammatory disease (n = 96).

	<25 y/o (A)	25-44 y/o (B)	≥45 y/o (C)	Total	P-value	Post-hoc
N	13	52	31	96		
No. of infected organ type	1.69±0.95	1.83±0.79	1.94±1.12	1.84±0.92	0.718	
Organism	-	-	-	-	-	
Vagina (%)	8(61.5%)	33(63.5%)	14(45.2%)	55(57.3%)	0.250	
Respiratory (%)	3(23.1%)	13(25.0%)	14(45.2%)	30(31.3%)	0.126	
Enteric (%)	8(61.5%)	39(75.0%)	19(61.3%)	66(68.8%)	0.356	
Skin (%)	1(7.7%)	3(5.8%)	5(16.1%)	9(9.4%)	0.254	
Oral (%)	2(15.4%)	7(13.5%)	5(16.1%)	14(14.6%)	0.923	
Other (%)	0(0.0%)	0(0.0%)	3(9.7%)	3(3.1%)	0.079	
No. of organism isolates	-	-	-	-	-	
Vagina	0.92±0.95	0.94±0.90	0.74±1.34	0.88±1.06	0.700	
Respiratory	0.23±0.44	0.29±0.54	0.65±0.92	0.40±0.69	0.046*	A <c< td=""></c<>
Enteric	0.69±0.63	1.15±0.92	1.29±1.85	1.14±1.27	0.362	
Skin	0.08±0.28	0.06±0.24	0.16±0.37	0.09±0.29	0.293	
Oral	0.23±0.60	0.17±0.47	0.16±0.37	0.18±0.46	0.898	
Other	0.00±0.00	0.00±0.00	0.10±0.30	0.03±0.18	0.039*	A <c< td=""></c<>
No. of total bacteria type	2.15±1.21	2.62±1.55	3.10±3.96	2.71±2.55	0.502	

Data are presented as n(%) or mean  $\pm$  standard deviation.

 $^*\mbox{p-value}{<}0.05$  was considered statistically significant after test.

y/o: year-old.

https://doi.org/10.1371/journal.pone.0257627.t002

<sup>\*</sup>p-value<0.05 was considered statistically significant after test.

Table 3. The numbers (percentage) of different categorial pathogens in pelvic inflammatory disease patients (n = 96).

	<25 y/o (A)	25-44 y/o (B)	≥45 y/o (C)	Total	P-value
N	13	52	31	96	
Vagina (10 types)	-	-	-	-	-
Bacteroid thetaiotaomicron	0(0.0%)	1(1.9%)	1(3.2%)	2(2.1%)	1.000
Bacteroid uniformis	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Bacteroides stercoris	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Bacteroides vulgatus	0(0.0%)	0(0.0%)	2(6.5%)	2(2.1%)	0.207
Clostridium ramosum	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Peptostreptococcus anaerobius	3(23.1%)	14(26.9%)	7(22.6%)	24(25.0%)	0.894
Peptostreptococcus species	5(38.5%)	19(36.5%)	7(22.6%)	31(32.3%)	0.369
Prevotella bivia	3(23.1%)	15(28.8%)	2(6.5%)	20(20.8%)	0.035*
Prevotella denticola	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Staphylococcus saprophyticus	1(7.7%)	0(0.0%)	0(0.0%)	1(1.0%)	0.135
Respiratory (12 types)	-	-	-	-	-
Acinetobacter baumannii (CRAB)	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Acinetobacter baumannii	0(0.0%)	2(3.8%)	0(0.0%)	2(2.1%)	0.646
Acinetobacter calcoaceticus complex	0(0.0%)	0(0.0%)	0(0.0%)	0(0.0%)	1.000
Haemophilus parainfluenzae	0(0.0%)	2(3.8%)	0(0.0%)	2(2.1%)	0.646
Klebsiella pneumonia	1(7.7%)	4(7.7%)	8(25.8%)	13(13.5%)	0.058
Prevotella melaninogenica	1(7.7%)	1(1.9%)	1(3.2%)	3(3.1%)	0.388
Pseudomonas aeruginosa	0(0.0%)	1(1.9%)	2(6.5%)	3(3.1%)	0.712
Serratia marcescens	0(0.0%)	0(0.0%)	2(6.5%)	2(2.1%)	0.207
Staphylococcus aureus	1(7.7%)	3(5.8%)	3(9.7%)	7(7.3%)	0.863
Staphylococcus aureus (ORSA)	0(0.0%)	2(3.8%)	2(6.5%)	4(4.2%)	0.794
Stenotrophomonas maltophilia	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
β-streptococci group A	0(0.0%)	0(0.0%)	0(0.0%)	0(0.0%)	1.000
Enteric (18 types)	-	-	-	-	-
Aeromonas hydrophila	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Aeromonas sobria	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Bacteroid fragilis	0(0.0%)	5(9.6%)	5(16.1%)	10(10.4%)	0.360
Bifidobacterium sp.	0(0.0%)	0(0.0%)	2(6.5%)	2(2.1%)	0.207
Citrobacter freundii	0(0.0%)	2(3.8%)	0(0.0%)	2(2.1%)	0.646
Enterobacter aerogenes	0(0.0%)	1(1.9%)	0(0.0%)	1(1.0%)	1.000
Enterococcus avium	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Enterococcus faecalis	2(15.4%)	8(15.4%)	4(12.9%)	14(14.6%)	1.000
Enterococcus faecium	0(0.0%)	2(3.8%)	1(3.2%)	3(3.1%)	1.000
Enterococcus	0(0.0%)	8(15.4%)	3(9.7%)	11(11.5%)	0.364
Escherichia coli	4(30.8%)	16(30.8%)	14(45.2%)	34(35.4%)	0.387
Morganella morganii	0(0.0%)	1(1.9%)	2(6.5%)	3(3.1%)	0.712
Prevotella species	0(0.0%)	0(0.0%)	0(0.0%)	0(0.0%)	1.000
Proteus mirabilis	0(0.0%)	0(0.0%)	3(9.7%)	3(3.1%)	0.079
Streptococcus bovis II	1(7.7%)	2(3.8%)	1(3.2%)	4(4.2%)	0.608
Streptococcus group D non enterococcus	0(0.0%)	1(1.9%)	0(0.0%)	1(1.0%)	1.000
Veillonella species	1(7.7%)	5(9.6%)	0(0.0%)	6(6.3%)	0.170
β-streptococci group B	1(7.7%)	9(17.3%)	2(6.5%)	12(12.5%)	0.323
Skin (1 type)	-	-	-	-	-
Coagulase-negative staphylococci	1(7.7%)	3(5.8%)	5(16.1%)	9(9.4%)	0.254
Oral (9 types)	-	-	-	-	-

(Continued)

Table 3. (Continued)

	<25 y/o (A)	25-44 y/o (B)	≥45 y/o (C)	Total	P-value
Fusobacterium nucleatum	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Fusobacterium species	1(7.7%)	0(0.0%)	0(0.0%)	1(1.0%)	0.135
Prevotella disiens	0(0.0%)	1(1.9%)	0(0.0%)	1(1.0%)	1.000
Prevotella intermedia	0(0.0%)	2(3.8%)	0(0.0%)	2(2.1%)	0.646
Prevotella oralis	1(7.7%)	0(0.0%)	1(3.2%)	2(2.1%)	0.105
Streptococcus anginosus	0(0.0%)	1(1.9%)	0(0.0%)	1(1.0%)	1.000
Streptococcus sanguis	0(0.0%)	1(1.9%)	0(0.0%)	1(1.0%)	1.000
Viridans streptococci	1(7.7%)	2(3.8%)	3(9.7%)	6(6.3%)	0.408
β-streptococci group G	0(0.0%)	2(3.8%)	0(0.0%)	2(2.1%)	0.646
Others (3 types)	-	-	-	-	-
Pantoea species	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Pasteurella species	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458
Shewanella putrefaciens	0(0.0%)	0(0.0%)	1(3.2%)	1(1.0%)	0.458

Data are presented as n(%).

https://doi.org/10.1371/journal.pone.0257627.t003

years groups than in the age  $\geq$ 45 years group (p = 0.035). The distribution *Klebsiella pneumonia* was not different among different age groups (p = 0.058).

<u>Table 4</u> shows the factors associated with vagina, respiratory, and enteric pathogens infections. After multivariate analysis, we could not find the factors associated with these pathogens' infections.

#### Discussion

Our study reviewed the medical records of 96 patients (31, 52, and 13 in the age  $\geq$ 45y group, 25–44, and <25 years groups, respectively). We found isolated respiratory and other pathogens were more common in the age  $\geq$ 45y group than the other two groups. The vagna and enteric pathogens were the most common among all groups. We found *Prevotella bivia* (vaginal pathogens) was more common in age <25 and 25–44 years groups than in the age  $\geq$ 45 years group. However, we could not find the association between age and microorganisms of different sources.

Eighty-five percent of PID cases are caused by sexually transmitted pathogens or bacterial vaginosis-associated pathogens [14]. Fewer than 50% of PID cases are now attributable to N. gonorrhoeae or C. trachomatis [6, 7]. By contrast, fewer than 15% of acute PID cases are not sexually transmitted and instead are associated with enteric or respiratory pathogens [15]. In our study, the distribution of microorganisms differed among the three groups. The percentage of pathogens from different origins were not different among the three groups. For isolated organisms, the respiratory and other pathogens were more in the age  $\geq$ 45y group.

Ness et al. examined 1140 patients aged 13–36 and found that vaginal and enteric pathogens are the most common non-sexually transmitted bacterial pathogens in younger patients [16]. The pathogenesis of PID in young patients is generally associated with high sexual activity; therefore, the causal organisms are vaginal and enteric pathogens. However, in our study, we found that both vagina and enteric pathogens were the most common pathogens among all groups.

Postmenopausal patients had lower sexual activity and a smaller endocervical canal, thus decreasing the ability of *C. trachomatis* and *N. gonorrhoeae* to attach [17]. One study also

<sup>\*</sup>p-value<0.05 was considered statistically significant after test.

Table 4. Factors associated with vagina/respiratory/enteric infection (n = 96).

Vagina		Respiratory	Respiratory		Enteric		
OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value		
-	-	-	-	-	-		
Reference	NA	Reference	NA	Reference	NA		
0.53(0.01, 23.53)	0.740	1.33(0.03, 51.88)	0.878	1.04(0.03, 40.76)	0.984		
3.03(0.04, 223.81)	0.613	1.99(0.04, 109.71)	0.736		0.362		
-	-	-	-	-	-		
Reference	NA	Reference	NA	Reference	NA		
0.00(NA)	1.000	0.00(NA)	1.000	1.19E10(NA)	1.000		
1.73(0.25, 12.05)	0.580	2.11(0.32, 14.06)	0.439	1.33(0.10, 17.96)	0.831		
0.21(0.01, 2.95)	0.246	6.51(0.36, 116.50)	0.203	0.00(NA)	0.997		
-	-	-	-	-	-		
Reference	NA	Reference	NA	Reference	NA		
9.11(0.70, 118.39)	0.091	0.12(0.01, 1.63)	0.112	0.35(0.01, 21.34)	0.619		
		1 ' ' '			0.339		
-	-	-	-	-	-		
Reference			NA	Reference	NA		
				<del> </del>	0.402		
-	-	-	-	-	_		
Reference	NA	Reference	NA	Reference	NA		
					0.996		
-	-	-	-	-	-		
Reference		Reference	NA	Reference	NA		
					0.898		
, , ,		1 1	-	1	-		
		+	NA		NA		
					0.136		
-		-	_	-	-		
Reference		Reference	NA	Reference	NA		
					1		
					-		
					NA		
					0.997		
-	-	-	-	-	-		
Reference	NA	Reference	NA	Reference	NA		
					0.996		
		-	0.500	-	0.550		
Reference		Reference	NA	Reference	NA		
					0.391		
, , ,				0.21(0.01, 7.42)	- 0.371		
				Reference	NA		
					0.998		
, , ,		1 ' '		<u> </u>			
					- NIA		
0.9(0.11, 7.45)	0.923	0.13(0.01, 2.58)	0.180	5.09(0.19, 135.87)	0.332		
	Reference 0.53(0.01, 23.53) 3.03(0.04, 223.81)  - Reference 0.00(NA) 1.73(0.25, 12.05) 0.21(0.01, 2.95)  - Reference 9.11(0.70, 118.39) 2.54(0.18, 35.57)  - Reference 2.73(0.24, 30.81)	OR (95% CI)         P-value           -         -           Reference         NA           0.53(0.01, 23.53)         0.740           3.03(0.04, 223.81)         0.613           -         -           Reference         NA           0.00(NA)         1.000           1.73(0.25, 12.05)         0.580           0.21(0.01, 2.95)         0.246           -         -           Reference         NA           9.11(0.70, 118.39)         0.091           2.54(0.18, 35.57)         0.49           -         -           Reference         NA           2.73(0.24, 30.81)         0.416           -         -           Reference         NA           0.2(0.01, 4.02)         0.296           -         -           Reference         NA           1.24(0.19, 7.86)         0.822           -         -           Reference         NA           2.94(0.23, 36.9)         0.403           -         -           Reference         NA           2.26(0.16, 32.32)         0.548           -         - <t< td=""><td>OR (95% CI)         P-value         OR (95% CI)           Reference         NA         Reference           0.53(0.01, 23.53)         0.740         1.33(0.03, 51.88)           3.03(0.04, 223.81)         0.613         1.99(0.04, 109.71)           -         -         -           Reference         NA         Reference           0.00(NA)         1.000         0.00(NA)           1.73(0.25, 12.05)         0.580         2.11(0.32, 14.06)           0.21(0.01, 2.95)         0.246         6.51(0.36, 116.50)           -         -         -           Reference         NA         Reference           9.11(0.70, 118.39)         0.091         0.12(0.01, 1.63)           2.54(0.18, 35.57)         0.49         0.17(0.01, 3.30)           -         -         -         -           Reference         NA         Reference           2.73(0.24, 30.81)         0.416         0.14(0.01, 3.36)           -         -         -         -           Reference         NA         Reference           0.2(0.01, 4.02)         0.296         7.26(0.46, 113.34)           -         -         -           -         -         -     &lt;</td><td>OR (95% CI)         P-value         OR (95% CI)         P-value           Reference         NA         Reference         NA           0.53(0.01, 23.53)         0.740         1.33(0.03, 51.88)         0.878           3.03(0.04, 223.81)         0.613         1.99(0.04, 109.71)         0.736           Reference         NA         Reference         NA           0.00(NA)         1.000         0.00(NA)         1.000           1.73(0.25, 12.05)         0.580         2.11(0.32, 14.06)         0.439           0.21(0.01, 2.95)         0.246         6.51(0.36, 116.50)         0.203           -         -         -         -           Reference         NA         Reference         NA           9.11(0.70, 118.39)         0.091         0.12(0.01, 1.63)         0.112           2.54(0.18, 35.57)         0.49         0.17(0.01, 3.30)         0.242           -         -         -         -         -           Reference         NA         Reference         NA           Reference         NA         Reference         NA           0.2(0.14, 4.02)         0.296         7.26(0.46, 113.34)         0.157           -         -         -         -</td></t<> <td>OR (95% CI)         P-value         OR (95% CI)         P-value         OR (95% CI)           -</td>	OR (95% CI)         P-value         OR (95% CI)           Reference         NA         Reference           0.53(0.01, 23.53)         0.740         1.33(0.03, 51.88)           3.03(0.04, 223.81)         0.613         1.99(0.04, 109.71)           -         -         -           Reference         NA         Reference           0.00(NA)         1.000         0.00(NA)           1.73(0.25, 12.05)         0.580         2.11(0.32, 14.06)           0.21(0.01, 2.95)         0.246         6.51(0.36, 116.50)           -         -         -           Reference         NA         Reference           9.11(0.70, 118.39)         0.091         0.12(0.01, 1.63)           2.54(0.18, 35.57)         0.49         0.17(0.01, 3.30)           -         -         -         -           Reference         NA         Reference           2.73(0.24, 30.81)         0.416         0.14(0.01, 3.36)           -         -         -         -           Reference         NA         Reference           0.2(0.01, 4.02)         0.296         7.26(0.46, 113.34)           -         -         -           -         -         -     <	OR (95% CI)         P-value         OR (95% CI)         P-value           Reference         NA         Reference         NA           0.53(0.01, 23.53)         0.740         1.33(0.03, 51.88)         0.878           3.03(0.04, 223.81)         0.613         1.99(0.04, 109.71)         0.736           Reference         NA         Reference         NA           0.00(NA)         1.000         0.00(NA)         1.000           1.73(0.25, 12.05)         0.580         2.11(0.32, 14.06)         0.439           0.21(0.01, 2.95)         0.246         6.51(0.36, 116.50)         0.203           -         -         -         -           Reference         NA         Reference         NA           9.11(0.70, 118.39)         0.091         0.12(0.01, 1.63)         0.112           2.54(0.18, 35.57)         0.49         0.17(0.01, 3.30)         0.242           -         -         -         -         -           Reference         NA         Reference         NA           Reference         NA         Reference         NA           0.2(0.14, 4.02)         0.296         7.26(0.46, 113.34)         0.157           -         -         -         -	OR (95% CI)         P-value         OR (95% CI)         P-value         OR (95% CI)           -		

Data are presented as OR (95% CI).

BMI: body mass index, PID: pelvic inflammatory disease, UTI: urinary tract infection, HTN: hypertension, DM: diabetes mellitus, GYN: gynecologic, NA: not available.

https://doi.org/10.1371/journal.pone.0257627.t004

 $<sup>^*\</sup>mbox{p-value}{<}0.05$  was considered statistically significant after test.

showed a 5-fold decrease of PID caused by C. Trachomatis with age (age 16–19 years compared to age 35–44 years), so it is important to evaluate the other causes of PID in older women [11]. The pathogenesis of PID in these patients is more likely direct extension from adjacent intra-abdominal viscera, such as appendicitis, diverticulitis, and bowel perforation, rather than ascending infection. Structural abnormalities such as fluid accumulation due to myoma, polyps, or malignancy such as squamous cell cervical carcinoma are also associated with an increased risk of developing PID in patients aged  $\geq$ 45 years [17]. Because of the potential for direct intra-abdominal infection, E. coli and Klebsiella are most frequently encountered rather than sexually transmitted pathogens in older patients [17]. Another study showed that bacterial vaginosis and trichomonas vaginalis were the most common pathogens responsible for PID among postmenopausal women [1]. About 11.5% of postmenopausal women are diagnosed with PID [1]. Our study makes up a deficiency in studying PID in older women. Respiratory and other pathogens were more isolated in the age  $\geq$  45 years group than the other two groups.

Other risk factors also play roles in PID. One study found that increasing parity, multiple sexual contacts, and associated pelvic organ prolapse are risk factors of PID [1]. However, in their patient population, there was no significant association with chronic illnesses, smoking, hypertension, DM, or UTI [1]. In our study, the common characteristics of the age  $\geq$  45 years group were the number of NSD, hypertension, DM, and menopause.

According to the CDC 2021 STD Treatment Guidelines for PID, empirical antibiotics with ceftriaxone and doxycycline are advised to treat infection of sexually transmitted pathogens [12]. However, routine treatment for aerobic pathogens and other pathogens remains controversial [12]. The current recommendation for the management of PID is focused on STD-related pathogens in younger patients. Our results showed respiratory pathogens play an important role among age  $\geq$  45 years women with PID which can help guide a more specific choice of antibiotic.

Prevotella bivia is anaerobic, gram-negative, bile-sensitive rods belonging to genus Bacteroides [18]. It may harbor metronidazole-resistant characteristics [19]. Nim gene is responsible for the resistance [20]. In our study, we found Prevotella bivia was more isolated pathogens in the age <25 years and 25–44 years group than in the age  $\ge$  45 years group. The antibiotics regimen contained metronidazole should be further evaluated for the younger age group.

Klebsiella pneumonia is a gram-negative bacteria found in human gut flora and causes pneumonia and genito-urinary infection commonly [21]. Most klebsiella are resistant to ampicillin [22]. K. pneumonia can cause a severe infection, such as meningitis or brain abscess, and can be life-threatening which needs advanced antibiotics treatment [23]. The previous study explored endocervical culture from 100 women and they found Klebsiella pneumonia occupied 2% of the study women [24]. The other study showed the prevalence of Klebsiella pneumonia infection in PID was 18.3% [25]. They also found the isolated K. pneumonia numbers were 24, 15, 10, 5 in the age 21–30, 31–40, 41–50 and >50 years group, respectively [25]. There seemed no difference among different age groups [25]. In our study, the distribution of K. pneumonia was also no different among different age groups.

This study has several limitations. First, this is a retrospective study that may have some data collection bias, and the sample size is small. Second, common pathogens such as *N. gonor-rhoeae* and *C. trachomatis* were not included in our study because special culture media should be used. Last, our study was based on a single center in eastern Taiwan and therefore our results may not be generalizable to other populations.

In conclusion, the most common non-STD-related pathogens in our study were enteric and vaginal pathogens among all aged patients. Respiratory pathogens were significantly more common in the age  $\geq$  45 years group than other two groups. As current guidelines for PID

treatment focus on younger patients and sexually transmitted pathogens, our study might be a reference for antibiotic choice in the broader population. More comprehensive studies should be done and further outcomes should be examined, particularly after antibiotic treatment.

# **Acknowledgments**

The authors thank Dr. Jeng-Hung Wang for his statistical assistance.

## **Author Contributions**

Conceptualization: Dah-Ching Ding.

Data curation: Pei-Chen Chen, Pei-Chen Li, Dah-Ching Ding.Formal analysis: Pei-Chen Chen, Pei-Chen Li, Dah-Ching Ding.

Funding acquisition: Dah-Ching Ding.

Investigation: Pei-Chen Chen, Pei-Chen Li, Dah-Ching Ding.Methodology: Pei-Chen Chen, Pei-Chen Li, Dah-Ching Ding.

Resources: Dah-Ching Ding.

Supervision: Dah-Ching Ding.

Validation: Dah-Ching Ding.

Visualization: Dah-Ching Ding.

Writing – original draft: Pei-Chen Chen, Pei-Chen Li, Dah-Ching Ding.
Writing – review & editing: Pei-Chen Chen, Pei-Chen Li, Dah-Ching Ding.

## References

- Khan S, Ansari MA, Vasenwala SM, Mohsin Z. A community based study on pelvic inflammatory disease in postmenopausal females: microbiological spectrum and socio-demographic correlates. J Clin Diagn Res. 2017; 11: LC05–LC10.
- Hollier LM, Workowski K. Treatment of sexually transmitted diseases in women. Obstet Gynecol Clin North Am. 2003; 30: 751–75, vii–viii. https://doi.org/10.1016/s0889-8545(03)00087-1 PMID: 14719849
- Rathore M, Swami SS, Gupta BL, Sen V, Vyas BL, Bhargav A, et al. Community based study of self reported morbidity of reproductive tract among women of reproductive age in rural area of rajasthan. Indian J Community Med. 2003; 28: 117.
- Hubacher D. Intrauterine devices & infection: review of the literature. Indian J Med Res. 2014; 140 Suppl: S53–7.
- 5. Gradison M. Pelvic inflammatory disease. Am Fam Physician. 2012; 85: 791–796. PMID: 22534388
- Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med. 2012; 30: 1114–1117. https://doi.org/10.1016/j.ajem.2011.07.014 PMID: 22030186
- Haggerty CL, Taylor BD. Mycoplasma genitalium: an emerging cause of pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2011; 2011: 959816. https://doi.org/10.1155/2011/959816 PMID: 22235165
- Xu J, Bian G, Zheng M, Lu G, Chan W-Y, Li W, et al. Fertility factors affect the vaginal microbiome in women of reproductive age. Am J Reprod Immunol. 2020; 83: e13220. <a href="https://doi.org/10.1111/aji.13220">https://doi.org/10.1111/aji.13220</a> PMID: 31925865
- Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med. 2015; 372: 2039–2048. https://doi.org/10.1056/NEJMra1411426 PMID: 25992748
- Curry A, Williams T, Penny ML. Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention. Am Fam Physician. 2019; 100: 357–364. PMID: 31524362

- Price MJ, Ades AE, Welton NJ, Simms I, Macleod J, Horner PJ. Proportion of Pelvic Inflammatory Disease Cases Caused by Chlamydia trachomatis: Consistent Picture From Different Methods. J Infect Dis. 2016; 214: 617–624. https://doi.org/10.1093/infdis/jjiw178 PMID: 27260786
- Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021; 70: 1–187. https://doi.org/10. 15585/mmwr.rr7004a1 PMID: 34292926
- Soper DE. Pelvic inflammatory disease. Obstet Gynecol. 2010; 116: 419–428. https://doi.org/10.1097/ AOG.0b013e3181e92c54 PMID: 20664404
- Jennings LK, Krywko DM. Pelvic Inflammatory Disease. StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
- Peipert JF, Ness RB, Blume J, Soper DE, Holley R, Randall H, et al. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol. 2001; 184: 856–63; discussion 863–4. https://doi.org/10.1067/mob.2001.113847 PMID: 11303192
- Ness RB, Kip KE, Hillier SL, Soper DE, Stamm CA, Sweet RL, et al. A Cluster Analysis of Bacterial Vaginosis—associated Microflora and Pelvic Inflammatory Disease. Am J Epidemiol. 2005; 162: 585–590. https://doi.org/10.1093/aje/kwi243 PMID: 16093289
- Jackson SL, Soper DE. Pelvic inflammatory disease in the postmenopausal woman. Infect Dis Obstet Gynecol. 1999; 7: 248–252. https://doi.org/10.1002/(SICI)1098-0997(1999)7:5<248::AID-IDOG8>3.0. CO:2-V PMID: 10524671
- Alauzet C, Mory F, Teyssier C, Hallage H, Carlier JP, Grollier G, et al. Metronidazole resistance in Prevotella spp. and description of a new nim gene in Prevotella baroniae. Antimicrob Agents Chemother. 2010; 54: 60–64. https://doi.org/10.1128/AAC.01003-09 PMID: 19805556
- Veloo ACM, Chlebowicz M, Winter HLJ, Bathoorn D, Rossen JWA. Three metronidazole-resistant Prevotella bivia strains harbour a mobile element, encoding a novel nim gene, nimK, and an efflux small MDR transporter. J Antimicrob Chemother. 2018; 73: 2687–2690. <a href="https://doi.org/10.1093/jac/dky236">https://doi.org/10.1093/jac/dky236</a> PMID: 29982676
- Veloo ACM, Baas WH, Haan FJ, Coco J, Rossen JW. Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019; 25: 1156.e9– 1156.e13. https://doi.org/10.1016/j.cmi.2019.02.017 PMID: 30802650
- Sharma R, Mashaal H, Anjum F, Akella J. A rare site of presentation of Klebsiella pneumoniae intraabdominal abscess. Chest. 2020; 158: A2600.
- 22. Naga O, Hakim MN. Infectious Diseases. Pediatric Board Study Guide. 2015; 193.
- 23. Wang B, Zhang P, Li Y, Wang Y. Klebsiella pneumoniae-induced multiple invasive abscesses: A case report and literature review. Medicine. 2019; 98: e17362. https://doi.org/10.1097/MD. 000000000017362 PMID: 31574882
- 24. Spencer THI, Umeh PO, Irokanulo E, Baba MM, Spencer BB, Umar AI, et al. Bacterial isolates associated with pelvic inflammatory disease among female patients attending some hospitals in abuja, Nigeria. South Afr J Epidemiol Infect. 2014; 8: 9–13. https://doi.org/10.4314/ajid.v8i1.3 PMID: 24653811
- 25. Eze EM, Unegbu VN, Ezebialu CU, Nneji IR. Prevalence of microorganisms associated with Pelvic inflammatory disease in reproductive aged women in Onitsha North, Anambra state, Nigeria. Nov Res Microbiol J. 2018; 2: 147–155.